Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

Inclusion Criteria: * Diagnosis of NCFBE confirmed by chest CT * 18-80 years old, inclusive at time of informed consent * BMI \>18 * Percent predicted FEV1 \> 40%, pre-bronchodilator * Stable for 90 days with any airway clearance technique (ACT) method(s) * Stable on standard of care (SOC) therapy for 90 days (includes cycling antibiotics, such as inhaled tobramycin, and long-term macrolide therapy) and not likely, in the opinion of the investigator, to require any changes to therapy during the duration of study participation * Fully vaccinated for COVID-19 (second dose of a 2-shot regimen or single dose of 1-shot regimen completed \>14 days prior to the screening visit) * Must be able to produce a sputum sample * If female and of childbearing potential, must be willing to use contraception for the duration of the study. Exclusion Criteria * Positive urine pregnancy test for women of childbearing potential (WOCBP) at screening and baseline visit * Active exacerbation ≤28 days prior to the baseline visit * Initiating or changing antibiotic, antiviral, or antifungal therapy ≤ 28 days prior to the baseline visit * Changing or initiating any vitamin C, glutathione or N-acetyl-cysteine-containing therapy or multivitamin within 30 says prior to the screening visit. * Positive COVID-19 diagnostic test (PCR or antigen) within 90 days prior to the screening visit. * Participated in other interventional drug or device studies within 30 days of the screening visit (Note: observationa…